Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma

Effects of BMP-2 and AdCMVBMP-2 on human OSCC cell lines proliferation. UMSCC-1 and UMSCC-74A were treated with rhBMP-2 protein (a, b), AdCMVBMP-2 (c, d), or AdCMVLacZ (e, f) for 24h. Proliferation of the cells was quantified by the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTT) for up to 4 days after exposure. Values are means +/- standard deviations. * P<0.01 vs. 0 MOI infection; # P<0.01 for 10, 500, 1000 MIO vs. 0 MOI; ** P<0.01 10, 100, 1000 MOI vs. 0 MOI.

Effects of BMP-2 on the expression of IL-8 and VEGF on human OSCC cell lines. UMSCC-1 and UMSCC-74A were treated with rhBMP-2 protein (0–500 ng/ml) for 24h. After 1, 2 and 3 days IL-8 and VEGF levels were quantified using an ELISA assay. For UMSCC-1, secretion of both IL-8 (a) and VEGF (c) was significantly decreased after treatment. For UMSCC-74A, IL-8 (b) was significantly increased at 48 and 72h in 100 and 500 ng/ml, but VEGF (d) led to nearly no difference after BMP-2 treatment (*P<0.01, **P<0.05 vs. 0 ng/ml BMP-2).

Effects of BMP-2 on tumor growth in vivo and angiogenesis in the tumor. OSSC cells were co-tranplanted with BMSCs with or without infection with AdCMVBMP-2 to deliver BMP in vivo. After 2–4 weeks in vivo, tumor weight (a) and volume (b) were determined and expressed as the mean±SD with n=7 per group. There was no statistically significant difference in tumor weight or volume at any time point. (c) Macroscopic view of the tumors after 2 weeks in vivo. The specimen on the left panel is UMSCC-74A co-transplanted with hBMSCs, and the right one is UMSCC-74A co-tansplanted with hBMSCs which were infected with AdCMVBMP-2. (d) The density of vessels in tumors is depicted as the mean±SD. There was no statistically significant difference in tumor vessel densities between the two groups.